Pharmaceutical combinations and their use in treating gastrointestinal disorders
CA 2388959 A1 · Owner: Billstein, Stephan Anthony · Inventors: Wilusz, Edward Joseph Jr.; Iwicki, Mark Thomas; Franco, Nicola
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a combination of a first agent including either a 5-HT4 receptor agonist or antagonist or a 5-HT3 receptor antagonist and a co-agent and pharmaceutical compositions and formulations containing the combination. The pharmaceutical combination may be employed for the treatment of altered gastrointestinal motility, sensitivity secretion or abdominal , disorders. The dosage is preferably oral. The preferred first agent is tegaserod.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 8, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 8, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 8, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.